Eicosanoids and Eosinophilic Inflammation of Airways in Stable COPD

Overview

Journal Int J Chron Obstruct Pulmon Dis

Publisher Dove Medical Press

Specialty Pulmonary Medicine

Date 2021 Jun 3

PMID 34079245

Citations 6

Authors

Natalia Celejewska-Wojcik

Aleksander Kania

Karolina Gorka

Pawel Nastalek

Krzysztof Wojcik

Anna Gielicz

Lucyna Mastalerz

Marek Sanak

Krzysztof Sladek

Affiliations

Soon will be listed here.

Abstract

Purpose: Lipid mediators, particularly eicosanoids, are associated with airway inflammation, especially with the eosinophilic influx. This study aimed to measure lipid mediators and cells in induced sputum, that could possibly reflect the inflammatory process in the bronchial tree of COPD subjects.

Patients And Methods: Eighty patients diagnosed with COPD and 37 healthy controls participated in the study. Induced sputum samples were ascertained for differential cell count and induced sputum supernatant concentrations of selected eicosanoids by the means of gas chromatography/mass spectrometry and high-performance liquid chromatography/tandem mass spectrometry.

Results: Increased sputum eosinophilia was associated with higher concentrations of selected proinflammatory eicosanoids. In COPD subjects prostaglandin D and 11-dehydro-thromboxane B correlated negatively with airway obstruction measured by FEV and FEV/FVC values. COPD subjects with disease exacerbations during past 12 months had significantly higher concentrations of prostaglandin D, 12-oxo-eicosatetraenoic acid and 5-oxo-eicosatetraenoic acid.

Conclusion: Stable COPD is often associated with eosinophil influx in the lower airways and elevated concentrations of eicosanoids that is reflected by some disease characteristics.

Citing Articles

Exploring the Potential Role of Metabolomics in COPD: A Concise Review.

Tirelli C, Mira S, Belmonte L, De Filippi F, De Grassi M, Italia M Cells. 2024; 13(6.

PMID: 38534319 PMC: 10969696. DOI: 10.3390/cells13060475.

Update on metabolomic findings in COPD patients.

Gea J, Enriquez-Rodriguez C, Agranovich B, Pascual-Guardia S ERJ Open Res. 2023; 9(5).

PMID: 37908399 PMC: 10613990. DOI: 10.1183/23120541.00180-2023.

Association between blood eosinophil count and small airway eosinophils in smokers with and without COPD.

Maetani T, Tanabe N, Sato A, Shiraishi Y, Sakamoto R, Ogawa E ERJ Open Res. 2023; 9(5).

PMID: 37868149 PMC: 10588801. DOI: 10.1183/23120541.00235-2023.

Metabolome Features of COPD: A Scoping Review.

Godbole S, Bowler R Metabolites. 2022; 12(7).

PMID: 35888745 PMC: 9324381. DOI: 10.3390/metabo12070621.

Role of Thymus and Activation-Regulated Chemokine in Allergic Asthma.

Luu Quoc Q, Moon J, Lee D, Ban G, Kim S, Park H J Asthma Allergy. 2022; 15:157-167.

PMID: 35153491 PMC: 8828566. DOI: 10.2147/JAA.S351720.

References

Mastalerz L, Celejewska-Wojcik N, Wojcik K, Gielicz A, Januszek R, Cholewa A . Induced sputum eicosanoids during aspirin bronchial challenge of asthmatic patients with aspirin hypersensitivity. Allergy. 2014; 69(11):1550-9. DOI: 10.1111/all.12512. View

Gao J, Iwamoto H, Koskela J, Alenius H, Hattori N, Kohno N . Characterization of sputum biomarkers for asthma-COPD overlap syndrome. Int J Chron Obstruct Pulmon Dis. 2016; 11:2457-2465. PMC: 5053388. DOI: 10.2147/COPD.S113484. View

Casanova C, Celli B, de-Torres J, Martinez-Gonzalez C, Cosio B, Pinto-Plata V . Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. Eur Respir J. 2017; 50(5). DOI: 10.1183/13993003.01162-2017. View

Singh D, Kolsum U, Brightling C, Locantore N, Agusti A, Tal-Singer R . Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014; 44(6):1697-700. DOI: 10.1183/09031936.00162414. View

Zahraei H, Guissard F, Paulus V, Henket M, Donneau A, Louis R . Comprehensive Cluster Analysis for COPD Including Systemic and Airway Inflammatory Markers. COPD. 2020; 17(6):672-683. DOI: 10.1080/15412555.2020.1833853. View

Chou K, Su K, Hsiao Y, Huang S, Ko H, Tseng C . Post-bronchodilator Reversibility of FEV and Eosinophilic Airway Inflammation in COPD. Arch Bronconeumol. 2017; 53(10):547-553. DOI: 10.1016/j.arbres.2017.01.014. View

Negewo N, McDonald V, Baines K, Wark P, Simpson J, Jones P . Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD. Int J Chron Obstruct Pulmon Dis. 2016; 11:1495-504. PMC: 4936821. DOI: 10.2147/COPD.S100338. View

Sanak M, Gielicz A, Nagraba K, Kaszuba M, Kumik J, Szczeklik A . Targeted eicosanoids lipidomics of exhaled breath condensate in healthy subjects. J Chromatogr B Analyt Technol Biomed Life Sci. 2010; 878(21):1796-800. DOI: 10.1016/j.jchromb.2010.05.012. View

Mastalerz L, Celejewska-Wojcik N, Wojcik K, Gielicz A, Cmiel A, Ignacak M . Induced sputum supernatant bioactive lipid mediators can identify subtypes of asthma. Clin Exp Allergy. 2015; 45(12):1779-89. DOI: 10.1111/cea.12654. View

10.

Siva R, Green R, Brightling C, Shelley M, Hargadon B, McKenna S . Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J. 2007; 29(5):906-13. DOI: 10.1183/09031936.00146306. View

11.

Huynh M, Malcolm K, Kotaru C, Tilstra J, Westcott J, Fadok V . Defective apoptotic cell phagocytosis attenuates prostaglandin E2 and 15-hydroxyeicosatetraenoic acid in severe asthma alveolar macrophages. Am J Respir Crit Care Med. 2005; 172(8):972-9. DOI: 10.1164/rccm.200501-035OC. View

12.

Koblizek V, Milenkovic B, Barczyk A, Tkacova R, Somfay A, Zykov K . Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE Study. Eur Respir J. 2017; 49(5). PMC: 5460642. DOI: 10.1183/13993003.01446-2016. View

13.

Hurst J, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R . Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010; 363(12):1128-38. DOI: 10.1056/NEJMoa0909883. View

14.

Sanak M, Gielicz A, Bochenek G, Kaszuba M, Nizankowska-Mogilnicka E, Szczeklik A . Targeted eicosanoid lipidomics of exhaled breath condensate provide a distinct pattern in the aspirin-intolerant asthma phenotype. J Allergy Clin Immunol. 2011; 127(5):1141-7.e2. DOI: 10.1016/j.jaci.2010.12.1108. View

15.

Yun J, Lamb A, Chase R, Singh D, Parker M, Saferali A . Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2018; 141(6):2037-2047.e10. PMC: 5994197. DOI: 10.1016/j.jaci.2018.04.010. View

16.

Celejewska-Wojcik N, Wojcik K, Ignacak-Popiel M, Cmiel A, Tyrak K, Gielicz A . Subphenotypes of nonsteroidal antiinflammatory disease-exacerbated respiratory disease identified by latent class analysis. Allergy. 2019; 75(4):831-840. PMC: 7216982. DOI: 10.1111/all.14141. View

17.

Gorska K, Paplinska-Goryca M, Nejman-Gryz P, Goryca K, Krenke R . Eosinophilic and Neutrophilic Airway Inflammation in the Phenotyping of Mild-to-Moderate Asthma and Chronic Obstructive Pulmonary Disease. COPD. 2016; 14(2):181-189. DOI: 10.1080/15412555.2016.1260539. View

18.

Rhee C . Phenotype of asthma-chronic obstructive pulmonary disease overlap syndrome. Korean J Intern Med. 2015; 30(4):443-9. PMC: 4497330. DOI: 10.3904/kjim.2015.30.4.443. View

19.

Fanning L, Boyce J . Lipid mediators and allergic diseases. Ann Allergy Asthma Immunol. 2013; 111(3):155-62. PMC: 4088989. DOI: 10.1016/j.anai.2013.06.031. View

20.

Inoue H, Nagase T, Morita S, Yoshida A, Jinnai T, Ichinose M . Prevalence and characteristics of asthma-COPD overlap syndrome identified by a stepwise approach. Int J Chron Obstruct Pulmon Dis. 2017; 12:1803-1810. PMC: 5490467. DOI: 10.2147/COPD.S133859. View